会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明专利
    • Flow resistance modulated aerosolized active agent delivery
    • 流动电阻调节的活性剂递送
    • JP2009136688A
    • 2009-06-25
    • JP2009002017
    • 2009-01-07
    • Nektar Therapeuticsネクター セラピューティックス
    • ANDREW CLARKESCHULER CARLOSPABOOJIAN STEVE
    • A61K9/12A61M15/00A61M11/00A61M16/00
    • A61M15/00A61M2016/0021A61M2202/064
    • PROBLEM TO BE SOLVED: To provide methods and devices for delivering an active agent formulation to the lung of a human patient, in which the active agent formulation may be in dry powder form, it may be nebulized, or it may be in admixture with a propellant, and the active agent formulation is delivered to a patient at a low inspiratory flow rate for an initial period of time to increase bioavailability of the active agent.
      SOLUTION: The device 104 for delivering an active agent formulation to the lung of a human patient comprises a flow resistance modulator that modulates resistance to the flow of the aerosolized active agent formulation to produce an initial target flow rate of the aerosolized active agent formulation in a manner that is independent of patient instruction and flow rate monitoring 106.
      COPYRIGHT: (C)2009,JPO&INPIT
    • 要解决的问题:为了提供将活性剂制剂递送到人类患者的肺中的方法和装置,其中活性剂制剂可以是干粉形式,其可以是雾化的,或者可以是 与推进剂混合,并且活性剂制剂以低吸入流速在初始时期递送给患者以提高活性剂的生物利用度。 解决方案:用于将活性剂制剂输送到人类患者的肺的装置104包括流阻阻抗调节剂,其调节对雾化活性剂制剂的流动的阻力以产生雾化活性剂的初始目标流速 以不同于患者指导和流量监测106的方式进行制定。版权所有(C)2009年,JPO&INPIT
    • 4. 发明申请
    • INCREASED DOSAGE METERED DOSE INHALER
    • 增加剂量计量剂吸入剂
    • WO2004041340A3
    • 2005-02-24
    • PCT/US0334473
    • 2003-10-30
    • NEKTAR THERAPEUTICSSCHULER CARLOSCLARK ANDREW RWALSH KEVIN RALSTON WILLIAM
    • SCHULER CARLOSCLARK ANDREW RWALSH KEVIN RALSTON WILLIAM
    • A61M15/00B65D83/14B65D83/52
    • B65D83/54A61M15/009
    • An aerosolization apparatus (100) comprises a container (105) containing a pharmaceutical formulation, the pharmaceutical formulation comprising an active agent and a propellant. The aerosolization apparatus (100) further comprises a metering chamber (130) in communication with the container (105), the metering chambe (130) adapted to hold a metered amount of the pharmaceutical formulation, a valve (140) to allow the metered amount of the pharmaceutical formulation to be released from the metering chamber (130) when the valve (140) is actuated, and a pressurizer (165) that applies pressure to the pharmaceutical formulation in the metering chamber (130) while the pharmaceutical formulation is being released from the metering chamber (130). In one version, the metering chamber (130) is sized so that at least 2 mg, and preferably at least 5 mg, of the active agent is be aerosolized for delivery to a user during inhalation.
    • 雾化装置(100)包括容纳药物制剂的容器(105),所述药物制剂包含活性剂和推进剂。 雾化装置(100)还包括与容器(105)连通的计量腔室(130),计量腔体(130)适于容纳计量的药物制剂,阀(140)允许计量量 所述药物制剂在所述阀(140)被致动时从所述计量室(130)释放;以及加压器(165),其在所述药物制剂被释放时向所述计量室(130)中的药物制剂施加压力 从计量室(130)。 在一个版本中,计量室(130)的尺寸使得至少2mg,优选至少5mg的活性剂被雾化以在吸入期间输送给使用者。